Geoff McDonough’s big plans for NodThera’s NLRP3; Enhertu leader steps down at Daiichinews2026-02-06T12:00:41+00:00February 6th, 2026|Endpoints News|
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosisnews2026-02-06T12:00:30+00:00February 6th, 2026|Endpoints News|
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdownnews2026-02-06T12:00:29+00:00February 6th, 2026|Endpoints News|
Illumina bets on healthcare after Trump administration’s NIH funding disruptionsnews2026-02-06T09:19:24+00:00February 6th, 2026|Endpoints News|
FDA chief Makary takes aim at Hims’ compounded Wegovy pill plansnews2026-02-05T23:52:28+00:00February 5th, 2026|Endpoints News|
Novo’s threat to sue Hims over Wegovy pill faces legal hurdlenews2026-02-05T21:25:38+00:00February 5th, 2026|Endpoints News|
Veradermics CEO has a great hair day with 122% pop in IPOnews2026-02-05T18:34:42+00:00February 5th, 2026|Endpoints News|
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trialnews2026-02-05T17:15:12+00:00February 5th, 2026|Endpoints News|
Bristol Myers draws pipeline excitement as several data readouts nearnews2026-02-05T15:50:01+00:00February 5th, 2026|Endpoints News|
